Kornimate/medical-research-clean huggingface dataset:
the incidence of pulmonary embolism during nephrectomy

Conditions: Pulmonary Embolism; Renal Cell Carcinoma; Nephrectomy

Summary: patients with renal carcinoma was reported at high incidence of perioperative pulmonary embolism from current study. the investigators aimed to determine the incidence and outcome of this group of patient in the tertiary-care, university hospital and the rate of intraoperative transesophageal echocardiography utility and outcome.

perioperative pulmonary embolism (pe) is the serious adverse event leading to major morbidity and mortality. the incidence of pe during urologic surgery was previously report at 0.9 - 1.1% with mortality rate less than 2%. but the recent study by fukazawa et al report the incidence of pe was 11% in renal cancer patients underwent nephrectomy with mortality rate as high as 33%. the risk factors associated with pe included major surgery, cancer, arrhythmia, massive bleeding and level of tumor thrombus in inferior vena cava. transesophageal echocardiography (tee) is a very helpful intraoperative monitoring tool in major, non-cardiac surgery to detect emboli and guide the hemodynamic management in severely unstable patients. but it requires sophisticate machine and well-trained operator, the rate of utilisation was still limited. the investigators aimed to determine the incidence of perioperative pe in renal cancer patients undergoing nephrectomy. the secondary outcomes include risk factors associated with perioperative pe, clinical outcomes, the rate of tee utilization in this operation and outcome.

Eligibility criteria:
inclusion criteria: * adult patients with renal cancer undergoing nephrectomy exclusion criteria: * patients with incomplete data
nimotuzumab plus paclitaxel and cisplatin as 1st line treatment for esophageal squamous cell cancer

Conditions: Esophageal Squamous Cell Cancer

Summary: nimotuzumab, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in some studies with head-neck cancers. advanced esophageal carcinoma have poor prognosis and majority of patients resistant to chemotherapy in china. in the investigators phase ii clinical trial proceeded before,the combination of paclitaxel with cisplatin showed good tolerance and efficacy to esophageal carcinoma. the investigators then initiated a prospective phase ii clinical trial with nimotuzumabplus paclitaxel/cisplatin as the 1st line treatment in advanced esophageal carcinoma to observe the efficacy and safety of the combination.


Eligibility criteria:
inclusion criteria: * having signed informed consent * age 18 to 75 years old * histologically confirmed esophageal squamous carcinoma, unresectable recurrent or metastatic disease,no prior palliative chemotherapy; no prior radiotherapy except radiotherapy at non-target lesion of the study more than 3 months,recurrence from last adjuvant chemotherapy or adjuvant radiotherapy should be longer than 6 months; no prior treatment of paclitaxel as adjuvant chemotherapy, total dose of cisplatin is less than 300mg/m2 if used in adjuvant chemotherapy * sex is not limited * measurable disease according to the recist criteria(diameter of the lesion should be more than 10mm by spiral ct or mri, more than 20mm by common ct, the date of image should be less than 15 days before enrollment) * karnofsky performance status ≥80 * life expectancy of ≥ 3 month * wbc \> 4,000/mm3, absolute neutrophil count ≥2000/mm3, platelet \> 100,000/mm3, hb \> 10g/dl(within 14 days before enrollment),alt and ast \< 2.5 times uln (≤5 times uln in patients with liver metastases),bilirubin level \< 1.0 times uln,serum akp \< 2.5 times uln,serum creatinine \< 1.0 times uln * no sever complication, such as active gastrointestinal bleeding, perforation, jaundice, obstruction, non-cancerous fever \> 38℃； * normal ecg and heart function * fertile patients must use effective contraception * good compliance exclusion criteria: * previous treatment of palliative chemotherapy or recurrence less than 6 months from time of last adjuvant chemo-/radiotherapy * known hypersensitivity to nimotuzumab,paclitaxel,cisplatin * only with brain or bone metastasis * tumor with length ≥ 10cm, liver metastasis covers more than 50% of liver,or lung metastasis covers more than 25% of lung * no measurable lesions, eg. pleural fluid and ascites * suffer from severe heart disease or disease with other important organs * chronic diarrhea or renal dysfunction * pregnancy or lactation period * other previous malignancy within 5 year, except non-melanoma skin cancer * chronic diarrhea * mentally abnormal or disable cognition,including cns metastasis
prevention of seasonal affective disorder

Conditions: Seasonal Affective Disorder (SAD)

Summary: a placebo controlled study evaluating the effectivess of medication in preventing seasonal affective disorder


Eligibility criteria:
inclusion criteria: (patient must meet these criteria in order to be eligible for this study.) * patient has a history of major depressive disorder (mdd) with a seasonal pattern. exclusion criteria: (patient cannot meet these criteria in order to be eligible for this study.) * patient has a current or past history of seizure disorder or brain injury. * patient has a history or current diagnosis of anorexia nervousa or bulimia. * patient has recurrent summer depression more frequently than winter depression. * patient has primary diagnosis of panic disorder, obsessive compulsive disorder (ocd), posttraumatic stress disorder (ptsd), acute distress disorder, bipolar ii disorder or other psychotic disorders. * patient has initiated psychotherapy within the last 3 months.
establishment and standardization of a platform for in-depth tumour profiling (tupro) in patients with advanced and metastatic high-grade adenocarcinoma of ovarian, tubal or peritoneal origin (tupro-gyn)

Conditions: Adenocarcinoma of Ovary; Adenocarcinoma, Tubular; Peritoneal Cancer

Summary: the aim of this prospective, multi-centre, exploratory research project is the establishment of a platform for in-depth tumour profiling in patients with advanced and metastatic high-grade adenocarcinoma (hgac) of ovarian, tubal or peritoneal origin.

tupro-gyn is part of the tumour profiler (tupro) research collaboration, which aims to help generate information about patients' individual tumour biology for patients with advanced malignancies, using innovative biotechnologies and computational analyses for in-depth molecular profiling. the tupro-gyn study focuses on improving treatment for patients with advanced ovarian, tubal, or peritoneal cancer, who often face poor outcomes and limited options after initial therapy. the study aims to use advanced molecular profiling technologies to identify specific characteristics of tumors that can be targeted with personalized treatments. by building a comprehensive platform for in-depth tumor analysis, the project hopes to discover new biomarkers and support future clinical trials that match treatments to the molecular profile of individual tumors, potentially leading to better patient outcomes.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * eastern cooperative oncology group performance status score ≤ 2 (not bedridden for more than 50% of waking hours) * primary or recurrent hgac of ovarian, tubal or peritoneal origin international federation of gynecology and obstetrics (figo) stage iii or iv * written informed consent according to national legal and regulatory requirements prior to any project specific procedures exclusion criteria: * any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the project leader may interfere with the project or affect patient compliance * legal incompetence

Keywords: advanced ovarian cancer high-grade adenocarcinoma tubal origin peritoneal origin metastatic cancer tumour profiling
research on the environment and children's health: retinoblastoma

Conditions: Retinoblastoma

Summary: the purpose of the research study is to learn more about the causes of retinoblastoma and to identify possible risk factors in the parents of patients with retinoblastoma. this kind of study is called an epidemiology study and is often done by interviewing people with and without the disease. in the case of a childhood disease, the researchers ask about experiences of the parents and children before the disease developed.

the purpose of the study is to investigate the role of paternal exposures in the etiology of sporadic heritable retinoblastoma (rbl). the study has a matched case-control design with a sample size of 255 pairs. cases will be children with sporadic heritable (rbl) identified from eight hospitals that together treat most of the rbl patients in the u.s. and canada. we will use regional controls matched on year of birth and state/province of residence identified by randomdigit-dialing (rdd). fathers and mothers of cases and controls will be interviewed by telephone about their occupational, medical, dietary, and personal exposures before the index child's conception. blood samples will be obtained on cases and their parents for dna isolation. the case's dna will be used to characterize the disease-causing rb1 mutation. the parent's dna will be used to detect the few instances in which a parent also has the rb1 mutation, i.e., the child's rbl is familial rather than sporadic.

Eligibility criteria:
inclusion criteria: * cases will be children with sporadic heritable rbl, i.e., bilateral rbl without a family history of the disorder. * cases will be diagnosed with retinoblastoma in an approximately 7-year period, beginning january 1, 1998 and continuing until the sample size is reached. * the case family must reside in the continental u.s., alaska, or canada. * the case family must have a telephone in the household. * the patient's physician must give permission to contact the parents of the case. * the biologic father or mother of the case must be available and consent to be interviewed. * the father or mother must speak english or spanish. * genetic counseling regarding rb1 gene mutation analysis must be done prior to registration onto study. exclusion criteria: - cases that do not meet the above criteria will be ineligible to participate and excluded from the study.

Keywords: retinoblastoma sporadic heritable retinoblastoma paternal exposures
intestinal microbiota in prostate cancer patients as a biomarker for radiation-induced toxicity (imprint)

Conditions: Prostate Cancer; Prostate Adenocarcinoma; Prostatic Neoplasms

Summary: radiotherapy (rt) of the abdomen and/or pelvis is known to cause acute and late gastrointestinal (gi) toxicities. while radiation dose and volume are known risk factors for developing such side effects, recent evidence suggests patterns of disturbance in the composition of the gi microbiota - so called "dysbiosis" - may also promote the host's susceptibility to gi toxicities through impaired intestinal barrier function and inflammation. the imprint-study aims to expand the current knowledge on the role of intestinal bacteria and their metabolites involved in the pathophysiology of radiation-induced gi toxicities by longitudinally examining the microbiota composition (feces), the associated metabolome (blood, feces and urine) and bacterial extracellular vesicles (bevs) (blood and feces).

the imprint-study is a prospective biomarker study assessing the impact of different treatment field sizes and associated radiation doses on the patient's microbiome and metabolome, whereby the link with radiation-induced gi toxicities will be emphasized. blood, urine and fecal samples will be longitudinally collected at 4 different time points: (1) shortly before, (2) during and (3) shortly after rt treatment, as well as (4) one-month post-rt. to our knowledge, this is the first clinical research project relating the impact of multiple radiation parameters on fecal-, urine- and blood-based biomarkers to risk of gi toxicities in a homogeneously defined study population.

Eligibility criteria:
inclusion criteria: * histologically proven (initial) adenocarcinoma of the prostate * localized (confined to primary site) and/or regional (spread to regional pelvic lymph nodes) disease stage at diagnosis * age ≥ 18 years * rt is an integral part of the treatment - primary, adjuvant or salvage * who performance status 0-2 * administration of androgen deprivation therapy (adt) before rt * absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * signed informed consent form (icf) according to ich/gcp and national/regional regulations exclusion criteria: * other primary tumor (except for non-melanoma skin cancer) diagnosed \< 5 years before enrollment * diagnosis of inflammatory bowel disease (e.g. crohn's disease or ulcerative colitis) * administration of systemic therapy during rt other that adt * subjected to antibiotic treatment or medically imposed dietary restrictions \< 1 month prior to enrollment * body mass index (bmi) \> 35 * administration of pelvic rt \< 1 year

Keywords: radiotherapy microbiome metabolome
education for recognition and management of delirium

Conditions: Delirium; Intensive Care Unit Syndrome; Nurse-Patient Relations

Summary: delirium is a disturbance in consciousness with reduced ability to focus, sustain, or shift attention that occurs over a short period of time and tends to fluctuate over the course of the day. 50% to 81.7% had delirium during their icu hospitalization. delirium is associated with increased physical restraint, ventilation use, length of icu stay, and mortality. however, there is no established delirium care pathway in target hospital. chen et al. (2014) demonstrated that structured assessment stations with immediate feedback may improve overall learning efficiency over an ebp workshop alone. however, no published delirium care education study has used osces as an intervention for healthcare professionals. the aim is to evaluate the effects of implementing a scenario-based education intervention, including objective structured clinical examinations (osces) on delirium care among healthcare professionals. this is a knowledge translation research, builds on eight years of delirium care research in university of wollongong, australia. the research will be undertaken at icus in a medical center in northern of taiwan. there are two phases: (1) systematic review to identify delirium screen tool, and (2) a randomized controlled trial was conducted to determine the effects of implementing a scenario-based education intervention, including osce (experimental group), and on-line education only (control group) focused on recognition and management of delirium. the hypothesis is: scenario-based education intervention, including osce can increase the competence and self-efficacy among healthcare professionals in delirium care.

osces are an integral aspect of all levels of medical education but limited to undergraduate nursing and allied health education. osces are rarely used in the workplace as learning activities with nursing and allied health clinicians. this is the reason why this education initiative was innovative. osces are simulated 'real life' clinical scenarios presented to clinicians who are required to demonstrate to an assessor the clinical tasks which form an osce scenario.

Eligibility criteria:
inclusion criteria: * registered nurse worked in acute care unit and care with critical patients * age \> 20 years old. exclusion criteria: * unwilling to involved the research

Keywords: delirium knowledge translation objective structured clinical examination evidence-based practice
intermittent hypoxia-hyperoxia training in cerebral venous outflow disorders (ihht-cvod)

Conditions: Cerebral Venous Outflow Disorders

Summary: this study aims to investigate the safety and efficacy of intermittent hypoxia-hyperoxia treatment in patients with cerebral venous outflow disorders.

cerebral venous outflow disorder (cvod), resulting from internal blockage, external oppression, or jugular valve incompetence, can cause hemodynamic disturbance and abnormal perfusion status. restricted applicable populations and limited benefits constrain the application of existing cvod management approaches. previous studies indicate intermittent hypoxia hyperoxia training (ihht) might improve circulatory status via hypoxic stimulation and allow hypoxic-related symptom amelioration through oxygen supply. thus, ihht might be a promising therapy for the cvod population. studies have so far proved inconclusive as to whether ihht is safe and effective for cvod. therefore, the present study aimed to investigate the safety and feasibility of ihht in patients with cerebral venous outflow disorder.

Eligibility criteria:
inclusion criteria: 1. age range from 18 to 80 years. 2. diagnosis of cvod confirmed by ce-mrv, dsa, ctv, or ultrasound, including cerebral venous sinus stenosis (cvss), internal jugular venous stenosis (ijvs), or internal jugular venous valve incompetence. 3. unexplained chronic neurological deficits or other symptoms \> 3 months. 4. signed informed consent from the patient or legally authorized representative. exclusion criteria: 1. life-threatening comorbidities. 2. clinical symptoms and signs explained by other diseases. 3. intracranial hypertension; moderate to severe intracranial/extracranial arterial stenosis. 4. history of ischemic/hemorrhagic stroke or cerebral endovascular surgery. 5. intracranial abnormalities, such as tumors, abscesses, vascular malformations, or cerebral venous sinus thrombosis. 6. confirmed sleep apnea, plateau residency, traveling history of altitude \> 1000m, or relative hypoxic exposure within last six months. 7. poor compliance.
benralizumab patient access programme study: retrospective study in uk severe asthma centres

Conditions: Asthma

Summary: retrospective secondary data collection observational chart review study. data collection and analysis will be performed on a cohort of patients who have previously been enrolled on the bpap. approximately 300 patients taking part in the bpap between april 2018 and november 2019 and who meet the eligibility criteria will be recruited to participate in the study. data for each participant in the study will be obtained retrospectively with a focus on obtaining data at baseline (12 months prior to first benralizumab dose or at first assessment in the severe asthma center if \<12 months), index date (date of first benralizumab dose) and at least up to 24 months after index date. primary objectives * to describe baseline demographic and clinical characteristics of severe eosinophilic asthma patients enrolled in the bpap * to describe background treatment patterns of severe eosinophilic asthma patients at baseline and after benralizumab initiation secondary objectives: * to describe clinical outcomes after initiation of benralizumab therapy in severe eosinophilic asthma patients treated with benralizumab at 12 and 24 months * to describe patients' adherence to benralizumab, persistence and discontinuation rates and reasons for discontinuation at 12 and 24 months


Eligibility criteria:
inclusion criteria: * patients enrolled on the bpap between april 2018 and november 2019 * patients who have at least 1 benralizumab injection and with at least 3 months followup data from the time of enrolment into the bpap * patients initiated on benralizumab outside of the bpap by october 30, 2019. * where cro employees conduct the data extraction, patients must be able and willing to give informed consent to participate in the study exclusion criteria: * currently receiving benralizumab or any other biologic drug for the treatment of asthma in a clinical trial * refusal or inability to provide informed consent where the cro will be collecting the data
clorhexidine versus povidone for the prevention of surgical site infection after cesarean section

Conditions: Surgical Wound Infection

Summary: many solutions are used for cleaning the skin of a patient previous to a surgery. although the efficacy of clorhexidine has been proved in other surgical procedures, there is only a retrospective study in cesarean section (they report no benefit of one solution over the other). the investigators would like to evaluate the difference in surgical site infection in patients after cesarean section comparing preparation of the skin with clorhexidine versus povidone.


Eligibility criteria:
inclusion criteria: * gestational age \> 32 weeks * emergency cesarean section exclusion criteria: * allergy to clorhexidine * allergy to povidone * evidence of infection in the surgical site * loss to follow up at 15 days * surgeries that due to the emergency of the case do not allow the five minutes of skin cleaning.

Keywords: surgical wound infection clorhexidine povidone
active vitamin d effect on left ventricular hypertrophy

Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism; Left Ventricular Hypertrophy

Summary: left ventricular hypertrophy (lvh) predicts mortality at start of dialysis. prevention of of lvh is important. it is not known whether secondary hyperparathyroidism might induce lvh. in the present study patients are randomised to 1.25 dihydroxycholecalciferol or no treatment to study the effect on lvh.


Eligibility criteria:
inclusion criteria: * chronic kidney disease (s-creatinin \> 150 and \< 600 mikrom) * secondary hyperparathyroidism (between 3-8 times the upper limit of our pth assay) * stable blood pressure during the last 6 months (less than (160/95) * b-hemoglobin \> 6 mmol/l * ekg with sinus rhythm and no sign of q-wave infarction * expected follow up 6 month exclusion criteria: * pregnancy * kidney transplantation * malignant disease

Keywords: ckd 3-4